

Section II. (Amendments to the Claims)

Please amend claims 6, 11-13 and 15-19, as set out in the following listing of claims 1-19.

1. (Original) A surface expression vector comprising any one or two or more of pgsB, pgsC and pgsA genes encoding poly-gamma-glutamic acid synthase complex and a gene encoding a spike antigen protein or a nucleocapsid antigen protein of SARS coronavirus.
2. (Original) The surface expression vector according to claim 1, wherein the spike antigen protein is SARS SA, SARS SB, SARS SC, SARS SD or SARS SBC.
3. (Original) The surface expression vector according to claim 1, wherein the nucleocapsid antigen protein is SARS NA, SARS NB or SARS N.
4. (Original) The surface expression vector according to claim 2, wherein the vector is pHCE2LB:pgsA-SARS SA, pHCE2LB:pgsA-SARS SC or pHCE2LB:pgsA-SARS SBC.
5. (Original) The surface expression vector according to claim 3, wherein the vector is pHCE2LB:pgsA-SARS NB or pHCE2LB:pgsA-SARS N.
6. (Currently Amended) A microorganism transformed by the expression vector of ~~any one claim 1 among claims 1-5~~.
7. (Original) The microorganism according to claim 6 wherein the microorganism is selected from the group consisting of *E. coli*, *Salmonella typhi*, *Salmonella typhimurium*, *Vibrio cholerae*, *Mycobacterium bovis*, *Shigella*, *Bacillus*, lactic acid bacterium, *Staphylococcus*, *Listeria monocytogenes*, and *Streptococcus*.
8. (Original) A method for producing a spike antigen protein or a nucleocapsid antigen protein of SARS coronavirus comprising culturing the microorganism of claim 6.
9. (Original) A vaccine for prevention of SARS virus comprising the spike antigen protein or the nucleocapsid antigen protein or the produced by the method of claim 8, as an effective ingredient.
10. (Original) The vaccine according to claim 9, wherein the antigen protein is an expressed form on the surface of microorganism, a crudely extracted form or a purified form.

11. (Currently Amended) The vaccine according to claim 9, wherein the vaccine ~~can~~ is adapted to be taken oral administration or in food.
12. (Currently Amended) The vaccine according to claim 9, wherein the vaccine is adapted for subcutaneous or intra-peritoneal injection.
13. (Currently Amended) The vaccine according to claim 9, wherein the vaccine is adapted for intranasal administration.
14. (Original) The method according to claim 8, wherein the microorganism is lactic acid bacterium.
15. (Currently Amended) A lactic acid bacterium, which is produced by the method of claim 14 and having the spike antigen protein or the nucleocapsid antigen protein of SARS coronavirus is expressed on ~~the~~ its surface.
16. (Currently Amended) A vaccine for prevention of SARS comprising the lactic acid bacterium of claim 15, an antigen protein extracted from said lactic acid bacterium, as an effective ingredient.
17. (Currently Amended) The vaccine according to claim 16, wherein the vaccine ~~can~~ is adapted to be taken by oral administration or in food.
18. (Currently Amended) The vaccine according to claim 16, wherein the vaccine is adapted for subcutaneous or intra-peritoneal injection.
19. (Currently Amended) The vaccine according to claim 16, wherein the vaccine is adapted for intranasal administration.